7Baggers
 Bryan Wahl: Lawyer by Day, Weekend MD  Orange County Business Journal Mon, 17 Nov 2025 17:06:21 GMT
 OC500 2025: BOBAK “BOBBY” AZAMIAN  Orange County Business Journal Mon, 17 Nov 2025 08:54:11 GMT
 Tarsus Stock: A Biotech Contender Navigating Growth and Losses  AD HOC NEWS Fri, 14 Nov 2025 08:26:05 GMT
 tarsus pharmaceuticals: record revenue masks deepening losses  AD HOC NEWS Tue, 11 Nov 2025 08:10:04 GMT
 (tars) price dynamics and execution-aware positioning  news.stocktradersdaily.com Sun, 09 Nov 2025 02:28:02 GMT
 wall street analysts are bullish on top healthcare picks  The Globe and Mail Thu, 06 Nov 2025 18:22:44 GMT
 Tarsus to Participate in Upcoming Investor Conference  Sahm Thu, 06 Nov 2025 08:00:00 GMT
 tarsus to participate in upcoming investor conference  GlobeNewswire Wed, 05 Nov 2025 22:05:00 GMT
 guggenheim maintains buy rating for tars, raises target to $87 |  GuruFocus Wed, 05 Nov 2025 15:47:36 GMT
 decoding tarsus pharmaceuticals inc (tars): a strategic swot ins  GuruFocus Wed, 05 Nov 2025 05:37:57 GMT
 tarsus pharmaceuticals inc (tars) q3 2025 earnings call highligh  GuruFocus Wed, 05 Nov 2025 05:17:53 GMT
 tarsus pharmaceuticals reports strong q3 2025 growth  TipRanks Wed, 05 Nov 2025 04:46:15 GMT
 Why Tarsus Pharmaceuticals’ Stock is Making Waves  TipRanks Tue, 04 Nov 2025 21:56:40 GMT
 Tarsus Pharmaceuticals (TARS) Q3 2025 Earnings: EPS of $(0.30) B  GuruFocus Tue, 04 Nov 2025 21:45:47 GMT
 tars reports strong q3 revenue boosted by xdemvy sales  GuruFocus Tue, 04 Nov 2025 21:45:37 GMT
 Tarsus Pharmaceuticals Reports Strong Q3 2025 Growth  TipRanks Tue, 04 Nov 2025 08:00:00 GMT
 tarsus pharmaceuticals reports q3 eps (30c), consensus (33c)  TipRanks Tue, 04 Nov 2025 08:00:00 GMT
 tarsus pharma q3 revenue beats estimates, driven by xdemvy sales  MarketScreener Tue, 04 Nov 2025 08:00:00 GMT

Tarsus Pharmaceuticals, Inc
(NASDAQ:TARS) 

TARS stock logo

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis cau...

Founded: 2016
Full Time Employees: 18
CEO / Co-Founder: Bobak Azamian 
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends